Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gemcabene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcabene SCHEMBL28467433 | 0.92 | ACLY (0.47) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL1082921 | 0.81 | ACLY (0.38) | CYP4F2CYP4A11ACLYACACBACACA | |
| Gemcabene SCHEMBL761631 | 0.80 | ACLY (0.55) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL28394389 | 0.79 | ACLY (0.37) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL4459363 | 0.79 | ACLY (0.37) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL27363932 | 0.79 | ACLY (0.37) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL2988405 | 0.78 | CYP4F2 (0.36) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL5531453 | 0.78 | ACLY (0.59) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL6258161 | 0.78 | ACLY (0.53) | CYP4F2CYP4A11ACLYACACBACACA | |
| Gemcabene SCHEMBL4184554 | 0.78 | ACLY (0.53) | CYP4F2CYP4A11ACLYACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248678-A1 | GEMCABENE FOR TREATING INFLAMMATION | NEUROBO PHARMACEUTICALS, INC. | 2023-08-10 | — | — | US | claimed |
| EP-1715891-B2 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES | WARNER LAMBERT CO (US) | 2014-08-13 | — | — | EP | claimed |
| US-20100215654-A1 | Methods of treating Osteoarthritis with IL-6 Antagonists | PFIZER, INC. (US) | 2010-08-26 | — | — | US | claimed |
| EP-1715891-B1 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES | WARNER LAMBERT CO (US) | 2010-04-21 | — | — | EP | claimed |
| US-20080145367-A1 | Methods of Treating Osteoarthritis with Il-6 Antagonists | WARNER-LAMBERT COMPAY, LLC | 2008-06-19 | — | — | US | claimed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | claimed |
| EP-1715891-A2 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 OR ANTI-IL6 RECEPTOR ANTIBODIES | Warner-Lambert Company LLC (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005080429-A2 | METHODS OF TREATING OSTEOARTHRITIS WITH ANTI-IL-6 OR ANTI-IL6 RECEPTOR ANTIBODIES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050148654-A1 | Statin-carboxyalkylether combinations | BISGAIER CHARLES L (US) | 2005-07-07 | — | — | US | claimed |
| EP-1539127-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1280522-B1 | COMBINATION OF CARBOXYALKYLETHERS WITH ANTIHYPERTENSIVES AND PHARMACEUTICAL USE | WARNER LAMBERT CO (US) | 2004-12-01 | — | — | EP | claimed |
| US-20040072903-A1 | Carboxyalkylether-acat inhibitors combinations | AUERBACH BRUCE JEFFREY (US) | 2004-04-15 | — | — | US | claimed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | claimed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1292363-A2 | CARBOXYALKYLETHER-ACAT INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2001093845-A2 | CARBOXYALKYLETHER-ACAT INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2001-12-13 | — | — | WO | claimed |
| CN-116710439-B | Substituted pyrazolopiperidine carboxylic acids | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | CYP4F2 1467/4885CYP4A11 3892/4885ACLY 3034/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | CYP4F2 3452/4885CYP4A11 1902/4885ACLY 560/4885 |
| US-20230248678-A1 | GEMCABENE FOR TREATING INFLAMMATION | CXCL8, IFNG, IL1B | CYP4F2 4793/4885CYP4A11 3071/4885ACLY 3052/4885 |
| US-20050148654-A1 | Statin-carboxyalkylether combinations | HMGCR, CETP, LCAT | CYP4F2 300/4885CYP4A11 167/4885ACLY 436/4885 |
| US-20040072903-A1 | Carboxyalkylether-acat inhibitors combinations | LCAT, CETP, ACAT2 | CYP4F2 1292/4885CYP4A11 462/4885ACLY 98/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | CYP4F2 535/4885CYP4A11 325/4885ACLY 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.